Sycamore Allergy Shots: Pla a 1/2/3 SCIT Guide for Eastern US
Sycamore allergy shots (SCIT) target the three IUIS-characterized Platanus allergens — Pla a 1, Pla a 2, and Pla a 3 — making American sycamore one of the most molecularly understood tree-pollen aeroallergens without FDA-standardized extract. Pla a 2 is recognized by 76.3% of sensitized patients. The critical pre-SCIT step is ruling out Pla a 3 LTP syndrome, where raw peach and hazelnut reactions can be systemic, not just oral.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
American Sycamoreis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
American Sycamore Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to american sycamore — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of american sycamore allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of american sycamore immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of american sycamore extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for american sycamore allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing american sycamore extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription american sycamore immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat american sycamore allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is American Sycamore?
The biology, taxonomy, and clinical fingerprint of American Sycamore — the foundation of how SCIT targets it.
American sycamore (Platanus occidentalis) releasing wind-borne pollen from male catkins along a riverside in the eastern United States, March–May.
- Scientific name
- Platanus occidentalis
- Family
- PlatanaceaePlane tree family
- Type
- Deciduous tree pollen
- Native to
- Eastern and central United States
- Allergen proteins
- Pla a 1 (major) — putative invertase inhibitor, 18 kDaPla a 2 (major) — polygalacturonase, 43–45 kDaPla a 3 — non-specific lipid transfer protein (nsLTP), 9 kDa
- Particle size
- 17–22 μm (tricolporate)
- Avoidance difficulty
- Very difficult
How American Sycamore Allergy Presents
Symptoms by body system — useful for distinguishing American Sycamore sensitivity from overlapping allergies and infections.
Respiratory
- Sneezing in prolonged bursts during March–May catkin release
- Nasal congestion and clear rhinorrhea
- Itchy or irritated nasal passages
- Coughing and throat irritation from airborne pollen
- Wheezing or worsened asthma in sensitized individuals
Ocular
- Itchy, watery eyes during peak pollen release
- Red or inflamed conjunctiva
- Periorbital puffiness
- Sensitivity to bright light during high-count days
Dermal
- Perioral tingling or itching after eating raw peach or hazelnut (Pla a 3 LTP syndrome)
- Contact urticaria from handling Platanus bark or leaves in sensitized individuals
- Hives in patients with significant Pla a 3 sensitization eating raw peanut
Systemic
- Fatigue from chronic allergic rhinitis during pollen season
- Sleep disruption due to nasal congestion
- Systemic anaphylaxis — rare but reported with Pla a 3 LTP food cross-reactivity (raw peach, hazelnut, peanut)
- Headache from chronic sinus inflammation
If your sycamore-allergic patient reacts to raw peach with throat tightness rather than just mouth itch, screen for Pla a 3 nsLTP before initiating SCIT — the LTP cross-reactivity is heat-stable and behaves more like a primary food allergy than classical pollen-food syndrome.
When & Where American Sycamore Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: April, with pollen release spanning 20–40 days from March through May· ~6–8 weeks of symptomatic exposure in most of the eastern and midwestern US
US Exposure Map
16 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Moderate
- WI:
- Moderate
- MI:
- Moderate
- NY:
- Moderate
- MA:
- Moderate
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Moderate
- IL:
- High
- IN:
- High
- OH:
- High
- PA:
- Moderate
- NJ:
- Moderate
- CT:
- Moderate
- RI:
- Moderate
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Moderate
- MO:
- High
- KY:
- High
- WV:
- High
- VA:
- High
- MD:
- Moderate
- DE:
- Moderate
- AZ:
- Low
- NM:
- Low
- KS:
- Moderate
- AR:
- High
- TN:
- High
- NC:
- High
- SC:
- High
- OK:
- High
- LA:
- Moderate
- MS:
- High
- AL:
- High
- GA:
- High
- TX:
- High
- FL:
- Moderate
- AK:
- Low
- HI:
- Low
What American Sycamore Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Sycamore pollen cross-reacts via three distinct molecular pathways: the major allergens Pla a 1 and Pla a 2 drive pollen-only sensitization, while Pla a 3 (nsLTP) drives heat-stable cross-reactivity with stone fruits, hazelnut, and peanut that can cause systemic reactions.
Pla a 3 nsLTP cross-reacts with peach Pru p 3; reactions heat-stable, can be systemic
Pla a 3 LTP cross-reactivity with hazelnut Cor a 8; systemic risk in sensitized patients
Pla a 3 cross-reacts with peanut Ara h 9 (nsLTP); screen before initiating SCIT
Plane Tree – Peach – Hazelnut – Peanut Syndrome
Pla a 3, the nsLTP of Platanus pollen, cross-reacts with stone-fruit and nut nsLTPs (Pru p 3, Cor a 8, Ara h 9). Unlike PR-10-mediated OAS, these reactions are heat-stable — cooking does NOT destroy the allergen. Reactions range from oral tingling to systemic anaphylaxis, making Pla a 3 screening mandatory before SCIT initiation.
Is SCIT Right for Your American Sycamore Allergy?
Answer five questions to estimate whether sycamore allergy shots are an appropriate next step for your spring symptoms.
How severe are your sycamore/spring tree-pollen symptoms each year?
The American Sycamore SCIT Protocol
Sycamore SCIT uses non-standardized aqueous Platanus extract in a standard build-up and maintenance schedule; the critical pre-initiation step is Pla a 3 LTP screening, since heat-stable food cross-reactivity must be counseled before the first injection.
Starting from a highly diluted vial (1:100,000 w/v), the extract concentration is increased incrementally each week. A board-certified allergist supervises dose escalation and adjusts the schedule based on any local or systemic reactions. With Curex, eligible patients run this same gradual build-up at home — the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, and a 30-minute observation follows each injection.
Once the target maintenance concentration (1:100 w/v) is reached and tolerated, injection intervals extend to monthly. Most patients notice meaningful symptom improvement during the second or third spring season on SCIT. Continued maintenance injections sustain the immunologic tolerance built during the build-up phase.
After completing a full 3–5 year course, many patients retain meaningful symptom reduction for 7–12 additional years. The decision to discontinue is individualized; patients with comorbid asthma or severe sensitization may benefit from longer courses.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for American Sycamore SCIT
No US randomized controlled trial specific to American sycamore SCIT exists; clinical practice extrapolates from European Platanus SCIT data and from the broader tree-pollen immunotherapy literature via the AAAAI Practice Parameter framework.
- Symptom score improvement, EU Platanus SCIT60%Subiza et al., Allergol Immunopathol, 1994 — Spanish cohort, clinical benefit demonstrated
- IgE reactivity to Pla a 2 in sensitized adults76%Asturias et al., Clin Exp Allergy 2002 — Madrid plane-pollen cohort, N=80+
- Pla a 1 + Pla a 2 combined recognition in Platanus-allergic patients80%Enrique et al., J Investig Allergol Clin Immunol 2002 — combined allergen recognition
European Platanus SCIT studies demonstrate clinical benefit, but no US RCT has been conducted for American sycamore specifically. Clinical use extrapolates from EU plane-pollen data and the AAAAI Practice Parameter framework (Cox et al., JACI 2011; Greenhawt et al., Ann Allergy Asthma Immunol 2023). The high Pla a 2 IgE reactivity (76.3%) provides a molecular basis for immunotherapy targeting, but patients should understand the evidence is extrapolated rather than US-RCT-proven.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
American Sycamore SCIT Side Effects
Sycamore SCIT side effects follow the standard pattern for tree-pollen immunotherapy; local injection-site reactions are common and expected, while systemic reactions are rare with proper dose escalation and at-home observation.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Typically resolves within 1–2 hours; ice application reduces discomfort | Rate 30–50% | Mild |
Injection-site redness and itching Expected during dose escalation; indicates allergen interaction | Rate 30–40% | Mild |
Large local reaction (>5 cm swelling) Prompts dose adjustment at the next visit; does not predict systemic risk | Rate 5–10% | Moderate |
Persistent local induration Resolves over 24–48 hours; antihistamine pre-medication may help | Rate 2–5% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Generalized urticaria or pruritus Managed with antihistamines; requires dose hold and medical evaluation | Rate 0.1–0.5% per injection | Moderate |
Rhinitis or conjunctivitis flare Typically manageable with standard antiallergic medications | Rate 0.1–0.3% per injection | Mild |
Mild bronchospasm More likely in patients with comorbid asthma; spirometry monitoring recommended | Rate 0.05–0.1% per injection | Moderate |
Anaphylaxis With Curex at-home SCIT, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, a prescribed epinephrine auto-injector is confirmed on hand, and you self-observe for 30 minutes after each injection | Rate <0.01% per injection | Severe |
Sycamore SCIT has traditionally been administered in a medical facility with epinephrine and resuscitation equipment available; for eligible patients, Curex makes safe at-home self-administration possible with a personalized Platanus serum sterile-compounded to USP <797>, a prescribed epinephrine auto-injector confirmed on hand, and the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff. A 30-minute observation accompanies each dose — the safety practice that has anchored SCIT in US care for decades.
SCIT vs Alternatives for American Sycamore
Sycamore-allergic patients have four evidence-based options; SCIT is the only disease-modifying treatment and the only one that may reduce symptoms for years after completing the course.
| Criterion | SCITBest | SLIT Drops | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Strong (EU RCT data) | Moderate (extrapolated) | Minimal (pollen inescapable) | Symptom control only |
| 5-yr cost | $3,500–$15,000 | $1,500–$4,000 | $0–$500/yr | $200–$1,200/yr |
| Duration | 3–5 years | 3–5 years | Indefinite | Indefinite |
| Convenience | At-home weekly then monthly self-injection | Daily at home | Requires behavior change | Daily pills/sprays |
| Safety | USP <797> serum; Virtual Shot Room–supervised dosing; 30-min self-observation | Self-administered | No medical risk | Generally safe |
| Lasting effect | 7–12 yrs post-course | Ongoing use needed | No lasting change | No lasting change |
SCITBest
SLIT Drops
Avoidance
Medications
SCIT provides the only disease-modifying outcome for sycamore allergy, with lasting benefit extending years after completing the course. Curex now delivers this same disease-modifying SCIT at home with pricing confirmed in a current program quote — a Platanus serum sterile-compounded to USP <797>, weekly self-injection with the first injection from each new vial or concentration supervised live in the Virtual Shot Room, and a prescribed epinephrine auto-injector confirmed on hand, all under board-certified allergist oversight, once Pla a 3 food cross-reactivity has been assessed.
What American Sycamore SCIT Actually Costs
Most major insurers cover sycamore SCIT under standard allergy benefit codes (95115, 95117, 95165) when prescribed by a board-certified allergist. Out-of-pocket cost depends on deductible and co-insurance; prior authorization is required by many plans. Curex IgE testing to confirm Platanus sensitization and component screen for Pla a 3 is typically reimbursable under diagnostic benefit codes.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your american sycamore allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
American Sycamore SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
The key molecular difference is the allergen protein family. Birch sensitization is driven by Bet v 1, a PR-10 protein that cross-reacts with apple, cherry, peach, and hazelnut via heat-labile OAS — cooking destroys the allergen. Sycamore sensitization driven by Pla a 3 (nsLTP) cross-reacts with peach and hazelnut via a heat-stable LTP protein — cooking does NOT eliminate the allergen, and reactions can be systemic rather than limited to the mouth. Pla a 1 and Pla a 2 are sycamore-specific major allergens with no direct birch equivalent. A board-certified allergist can differentiate the two via component-resolved IgE testing.
This is a nuanced question. Sycamore SCIT targeting Pla a 1 and Pla a 2 is expected to reduce pollen-driven rhinitis. For patients also sensitized to Pla a 3 (the nsLTP that drives peach and hazelnut cross-reactivity), there is limited published evidence that SCIT meaningfully reduces food cross-reactions. The more immediate clinical priority is to document whether your Pla a 3 reactions are limited to oral tingling or include systemic symptoms — systemic reactions require an epinephrine auto-injector prescription regardless of SCIT status. A board-certified allergist will screen for this before initiating your build-up phase.
American sycamore typically releases pollen from late March through May across most of its native eastern and central US range, with peak levels in April. The pollen release period lasts 20–40 days — longer than many spring tree pollens. Per Anderegg et al. (PNAS 2021), North American tree-pollen seasons have shifted approximately 20 days earlier since 1990 due to climate change, so eastern US residents should expect sycamore symptoms to begin earlier than legacy allergy calendars suggest. The riparian (riverside) habitat of sycamore can create locally intense pollen corridors during peak release.
No FDA-standardized Platanus extract exists for sycamore as of May 2026. Sycamore SCIT uses non-standardized aqueous extracts from US manufacturers such as Greer, ALK, and Jubilant HollisterStier. Non-standardized means that potency may vary between batches and manufacturers. The AAAAI Practice Parameter (Cox et al., JACI 2011) recommends building doses to a clinically effective maintenance level within published ranges rather than relying strictly on label potency. European SCIT preparations for Platanus are better characterized, but US practice operates with non-standardized extracts and in-office dose escalation.
Antihistamines are generally safe to continue during sycamore SCIT and do not interfere with the immunological mechanism of immunotherapy. Many allergists actually recommend cetirizine or levocetirizine pre-medication before build-up injections to reduce local injection-site reactions. The important restrictions involve beta-blockers (which impair epinephrine response to anaphylaxis) and ACE inhibitors (which may increase systemic reaction risk) — discuss all medications with your prescribing allergist before starting SCIT. Nasal steroids and inhaled corticosteroids for comorbid asthma are fully compatible with sycamore immunotherapy and should be continued as prescribed. Reassuringly, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots.
Missing one or two injections during the build-up phase typically means restarting from a lower dose rather than continuing where you left off, to avoid systemic reactions from a gap in tolerance. The exact stepback depends on how long the gap was — generally, a gap of more than 2 weeks during build-up requires dose reduction. During the maintenance phase, a gap of up to 6–8 weeks is often tolerable without dose stepback, but your allergist will decide based on your individual history. Always notify your allergist of any missed injection before your next scheduled appointment rather than appearing and receiving the scheduled dose.
Most major health insurers cover sycamore SCIT under standard allergy immunotherapy benefit codes (CPT 95115, 95117, and 95165 for extract preparation) when prescribed by a board-certified allergist with documented IgE-mediated sensitization. Prior authorization is typically required, and some plans require documented failure of 6–12 months of pharmacotherapy before approving immunotherapy. Annual out-of-pocket costs under typical commercial insurance range from a few hundred to a few thousand dollars depending on your deductible and co-insurance levels. Confirm coverage with your insurer before initiating.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.